Publication

Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway

Lippa, Carol F.
Saunders, Ann M.
Smith, Thomas W.
Swearer, Joan M.
Drachman, David A.
Ghetti, Bernardino
Nee, Linda
Pulaski-Salo, D.
Dickson, Dennis
Robitaille, Yves
... show 8 more
Embargo Expiration Date
Abstract

Whether all etiologic forms of Alzheimer's disease (AD) share a final common pathway is a major issue. We determined the severity and regional distribution of neuronal loss, amyloid plaques, neuritic plaques (NPs), and neurofibrillary tangles (NFTs), and calculated the ratio of neuronal loss to NPs and NFTs in brains of 19 familial AD (FAD) patients with linkage to chromosome 14, six AD patients with mutations of chromosome 21 (codon 717 of the beta-amyloid percursor protein gene), and 11 sporadic AD (SAD) patients. There was no difference in the pattern of distribution of the various pathologic features or in the ratio of neuronal loss to NPs or NFTs in any AD group. However, FAD groups could be distinguished from SAD by the greater severity and the lack of influence of apolipoprotein E genotype on pathology. These differences may reflect differences in age at onset rather than different etiopathologic mechanisms. The similarity of pathologic findings in the different AD groups provides evidence for a final common pathophysiologic pathway in AD.

Source

Lippa CF, Saunders AM, Smith TW, Swearer JM, Drachman DA, Ghetti B, Nee L, Pulaski-Salo D, Dickson D, Robitaille Y, Bergeron C, Crain B, Benson MD, Farlow M, Hyman BT, George-Hyslop SP, Roses AD, Pollen DA. Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway. Neurology. 1996 Feb;46(2):406-12. doi: 10.1212/wnl.46.2.406. PMID: 8614503.

Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.1212/wnl.46.2.406
PubMed ID
8614503
Other Identifiers
Notes
Funding and Acknowledgements
Corresponding Author
Related Resources
Related Resources
Repository Citation
Rights
Distribution License